Patents Assigned to NeuroSystec Corporation
-
Patent number: 8298176Abstract: Drug solutions (or other combinations of vehicle with entrained drug) are prepared by removing drug from one or more masses of a solid form of the drug. The solid form of the drug may be sparingly soluble or insoluble in water. Examples of devices for holding solid drug and facilitating delivery of such drug to targeted regions are also described.Type: GrantFiled: July 19, 2010Date of Patent: October 30, 2012Assignee: NeuroSystec CorporationInventors: Thomas J. Lobl, Anna Imola Nagy, Jacob E. Pananen, John V. Schloss
-
Patent number: 8267905Abstract: Implantable drug delivery systems target delivery of small volumes of drugs to specific tissues. In some cases, a drug delivery system includes an implantable osmotic pump connected to a drug-containing housing, with that housing connected to a needle, cochlear implant or other type of component for ultimate delivery to the target tissue. In some implementations, a subcutaneous port receives a fluid from an external pump. The port is connected to a needle or other component for delivery of one or more drugs to the target tissue. Both solid and liquid drug formulations can be used. In embodiments using solid drugs, a separate drug vehicle (such as saline) can be used to dissolve a portion of the solid drug, with the drug-loaded vehicle then delivered to the target tissue.Type: GrantFiled: May 1, 2006Date of Patent: September 18, 2012Assignee: NeuroSystec CorporationInventors: Thomas J. Lobl, Stephen J. McCormack, Anna Imola Nagy, Jacob E. Pananen, John V. Schloss
-
Publication number: 20120208848Abstract: Improved formulations of gacyclidine for direct administration to the inner or middle ear.Type: ApplicationFiled: April 25, 2012Publication date: August 16, 2012Applicant: NEUROSYSTEC CORPORATIONInventors: Thomas Jay Lobl, John Vinton Schloss, Jacob E. Pananen
-
Publication number: 20120208851Abstract: Colloidal suspensions comprising a therapeutic agent and squalene. Squalene binds to certain compounds, such as gacyclidine, much more tightly than other drug carriers, such as polylactic glycolic acid. Including squalene in the particulate phase sequesters the therapeutic agent and provides superior stability at room or body temperature.Type: ApplicationFiled: June 18, 2009Publication date: August 16, 2012Applicant: NEUROSYSTEC CORPORATIONInventors: John Vinton Schloss, Thomas Jay Lobl
-
Publication number: 20110136870Abstract: Improved formulations of gacyclidine for direct administration to the inner or middle ear.Type: ApplicationFiled: February 4, 2011Publication date: June 9, 2011Applicant: NEUROSYSTEC CORPORATIONInventors: Thomas Jay Lobl, John Vinton Schloss, Stephen Joseph McCormack, Anna Imola Nagy, Jacob E. Pananen
-
Publication number: 20110071493Abstract: Drug solutions (or other combinations of vehicle with entrained drug) are prepared by removing drug from one or more masses of a solid form of the drug. The solid form of the drug may be sparingly soluble or insoluble in water. Examples of devices for holding solid drug and facilitating delivery of such drug to targeted regions are also described.Type: ApplicationFiled: July 19, 2010Publication date: March 24, 2011Applicant: NEUROSYSTEC CORPORATIONInventors: Thomas J. Lobl, Anna Imola Nagy, Jacob E. Pananen, John V. Schloss
-
Patent number: 7803148Abstract: Drug solutions (or other combinations of vehicle with entrained drug) are prepared by removing drug from one or more masses of a solid form of the drug. The solid form of the drug may be sparingly soluble or insoluble in water. Examples of devices for holding solid drug and facilitating delivery of such drug to targeted regions are also described.Type: GrantFiled: June 7, 2007Date of Patent: September 28, 2010Assignee: NeuroSystec CorporationInventors: Thomas J. Lobl, Anna Imola Nagy, Jacob E. Pananen, John V. Schloss
-
Publication number: 20090209945Abstract: A drug-delivery unit suitable for implantation into a patient body may include a valveless impedance pump. In some implementations the unit may include an actuator, control electronics and a battery, and may communicate with an external patient interface unit. The patient interface unit can be used to control operation of the implant and to download data from the implant. The patient interface unit can also be used to charge the implant and/or a separate charger can be used. In other implementations, a drug-delivery implant unit may lack internal electronics and instead rely on an externally-supplied magnetic field to actuate the pump.Type: ApplicationFiled: January 19, 2009Publication date: August 20, 2009Applicant: NEUROSYSTEC CORPORATIONInventors: Thomas J. Lobl, Jacob E. Pananen, David L. Canfield, Anna I. Nagy, Adrian L. Krag
-
Publication number: 20080152694Abstract: Devices, systems and techniques for delivering drugs to an ocular tissue are described. In at least some embodiments, a terminal component (e.g., a needle or open end of a catheter) is implanted in an ocular tissue and used to deliver one or more drugs. The delivered drugs may come from a source which is also implanted, or may be introduced from an external source (e.g., via a port). Both solid and liquid drug formulations can be used. Ocular implants can alternatively include a thin film coating that releases a drug into an ocular tissue.Type: ApplicationFiled: July 20, 2007Publication date: June 26, 2008Applicant: NEUROSYSTEC CORPORATIONInventors: Thomas J. Lobl, Anna Imola Nagy, Jacob E. Pananen, John V. Schloss
-
Publication number: 20080145439Abstract: A suspension of nanoparticles in a liquid medium provides a mechanism for delivery of gacyclidine base or other drug that is substantially insoluble in the liquid medium.Type: ApplicationFiled: July 31, 2007Publication date: June 19, 2008Applicant: NEUROSYSTEC CORPORATIONInventors: Thomas J. Lobl, John V. Schloss, Anna Imola Nagy, Jacob E. Pananen
-
Publication number: 20080065002Abstract: A drug-compatible, biocompatible, drug-delivery catheter can include multi-lumen tubing attached to an end fitting, with the end fitting having an internal fluid chamber and a fluid exit region. The catheter can also include multi-lumen tubing having one or more needles attached at a distal end.Type: ApplicationFiled: September 5, 2007Publication date: March 13, 2008Applicant: NEUROSYSTEC CORPORATIONInventors: Thomas J. Lobl, John V. Schloss, Anna Imola Nagy, Jacob E. Pananen
-
Publication number: 20070287984Abstract: Drug solutions (or other combinations of vehicle with entrained drug) are prepared by removing drug from one or more masses of a solid form of the drug. The solid form of the drug may be sparingly soluble or insoluble in water. Examples of devices for holding solid drug and facilitating delivery of such drug to targeted regions are also described.Type: ApplicationFiled: June 7, 2007Publication date: December 13, 2007Applicant: NEUROSYSTEC CORPORATIONInventors: Thomas J. Lobl, Anna Imola Nagy, Jacob E. Pananen, John V. Schloss
-
Publication number: 20070255237Abstract: Implantable drug delivery systems target delivery of small volumes of drugs to specific tissues. In some cases, a drug delivery system includes an implantable osmotic pump connected to a drug-containing housing, with that housing connected to a needle, cochlear implant or other type of component for ultimate delivery to the target tissue. In some implementations, a subcutaneous port receives a fluid from an external pump. The port is connected to a needle or other component for delivery of one or more drugs to the target tissue. Both solid and liquid drug formulations can be used. In embodiments using solid drugs, a separate drug vehicle (such as saline) can be used to dissolve a portion of the solid drug, with the drug-loaded vehicle then delivered to the target tissue.Type: ApplicationFiled: May 1, 2006Publication date: November 1, 2007Applicant: NeuroSystec CorporationInventors: Thomas Lobl, Stephen McCormack, Anna Nagy, Jacob Pananen, John Schloss
-
Publication number: 20060264897Abstract: An apparatus may include a needle for sustained delivery of drugs and other agents to the inner ear or other tissues of a human or an animal. The needle can include an insertion stop, and can be placed through the round window membrane or through a surgically-prepared hole in a bone. The needle can be in fluid communication with a port and/or with a micro-infusion or osmotic pump. A cochlear implant electrode can be used instead of a needle.Type: ApplicationFiled: January 24, 2006Publication date: November 23, 2006Applicant: NeuroSystec CorporationInventors: Thomas Lobl, Stephen McCormack, Thomas Lenarz, John Schloss, Anna Nagy, Jacob Pananen
-
Publication number: 20060205789Abstract: Improved formulations of gacyclidine for direct administration to the inner or middle ear.Type: ApplicationFiled: March 6, 2006Publication date: September 14, 2006Applicant: NeuroSystec CorporationInventors: Thomas Lobl, John Schloss, Stephen McCormack, Anna Nagy, Jacob Pananen